TScan Therapeutics, Inc. (TCRX) NASDAQ

Currency In USD

TScan Therapeutics, Inc.

Address

830 Winter Street

Waltham, MA 02451

United States of America (the)

Phone

857 399 9500

Website

https://www.tscan.com

Sector

Healthcare

Industry

Biotechnology

Employees

200

First IPO Date

July 16, 2021

Key Executives

Name	Title	Pay	Year Born
Gavin MacBeath	Chief Executive Officer & Director	818,650	1970
Jason A. Amello	CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer	606,800	1968
Chrystal U. Louis	Chief Medical Officer	618,200	1976
Zoran Zdraveski	Chief Legal & Strategy Officer and Company Secretary	657,200	1970
Shrikanta Chattopadhyay	Senior Vice President & Head of Translational Medicine	0	N/A
Stephen J. Elledge	Co-Founder & Chairman of Scientific Advisory Board	0	N/A
Cagan Gurer	Senior Vice President of Discovery	0	N/A
Jim Murray	Chief Development Operations Officer	0	N/A
Stephen Camiolo	Senior Vice President of Market Access	0	N/A
Tomasz Kula	Co-Founder & Member of Advisory Board	0	N/A
Ann Hargraves	Chief Human Resources Officer	0	N/A
Ray Lockard	Chief Manufacturing & Quality Officer	0	N/A

Description

TScan Therapeutics, Inc. is a biopharmaceutical enterprise, currently in its preclinical development stage, focused on engineering T cell receptor (TCR) therapies to combat various cancers. The company's pipeline features programs like TSC-100 and TSC-101, which are engineered to address blood cancers by clearing remnant leukemia cells and averting disease recurrence following hematopoietic stem cell transplantation. Additionally, TScan is advancing multiple candidates, including TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, targeting solid tumor indications. Beyond its oncology efforts, the company is also engaged in vaccine development for infectious agents, such as SARS-CoV-2. TScan has formed a strategic collaboration and licensing arrangement with Novartis Institutes for BioMedical Research, Inc., aimed at pinpointing novel cancer-specific antigens derived from the T cells of particular cancer patients. Founded in 2018, TScan Therapeutics, Inc. operates from its headquarters in Waltham, Massachusetts.